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Introduction 
 
Cardiovascular and cerebrovascular diseases are among the leading causes of death in 
developed countries. The classic risk factors for the development of atherosclerosis and 
atherothrombosis are now well known, e.g. hypertension, diabetes mellitus, smoking, 
obesity. However, the exact pathomechanism of arterial thrombosis is unknown in many 
respects, although better understanding of the factors leading to the development of 
thrombosis may serve to detect and treat cardiovascular and cerebrovascular diseases 
earlier in the future. A consensus paper published in 2018 by more than 60 
internationally acknowledged researchers stated that more intense research is necessary 
on the pathomechanism of thrombosis and investigating new potential biomarkers as 
diagnostic and prognostic tool of atherothrombotic diseases. 
One of the key factors in the development of arterial thrombosis is the disintegration of 
the balance of hemostasis system. However, the role of some markers of coagulation 
and fibrinolysis in the development of atherothrombotic events is less explored than in 
case of venous thromboembolic events. Meta-analyses and prospective studies have 
been found to have a positive correlation with the risk of coronary artery disease and 
stroke for only a few key factors (e.g. fibrinogen, von Willebrand factor, tissue 
plasminogen activator inhibitor) so far. These studies are far from complete, but the 
findings so far outline the idea that coagulation plays an important role in the 
progression of atherothrombotic processes. Studying the differences in the hemostasis 
system can not only provide a better understanding of the pathomechanism but 
hemostasis factors as biomarkers can provide useful information about the presence, 
severity and prognosis of the disease. In the Maastricht Consensus Statement experts 
also pointed out that studying certain factors (von Willebrand factor, factor VIII, factor 
IX, factor XI, factor XII) is also important in atherothrombotic diseases because they 
may become potential therapeutic targets in the future.  
Among cardiovascular diseases atrial fibrillation is characterized by high-risk arterial 
thrombosis (leading to stroke). It is widely recognized that thromboembolism in AF is 
associated with a combination of pathophysiological mechanisms, which fulfill the 
requirement of Virchow’s triad for thrombogenesis: stasis, abnormal change in the 
vessel wall and pathological imbalance of hemostasis and fibrinolysis. Several studies 
have been carried out to investigate the hypercoagulability in atrial fibrillation, but the 
 3 
starting process that activates the coagulation cascade is not yet clear during atrial 
fibrillation. The examination of the overt hemostasis equilibrium can best be performed 
by analyzing intracardiac blood samples, since the starting point of the differences is the 
left atrium itself. By analyzing blood samples obtained from the left atrium, we can get 
to know the pathomechanism of enhanced arterial thrombosis propensity associated 
with atrial fibrillation and potentially identify markers whose examination can help to 
predict stroke. 
In the case of an established stroke, the outcome of the therapy depends on the 
localization, size and structural features of the thrombus formed. The hemostasis 
changes accompanying the acute thrombotic process and the knowledge of hemostasis 
in the applied therapy allow a better understanding of the therapeutic outcomes. At 
present, intravenous thrombolysis with recombinant tissue plasminogen activator is the 
only registered drug for acute ischemic stroke therapy, but recently mechanical 
thrombectomy is also available. However, the rate of recanalization and clinical 
outcome in the treated patients is very different, and according to our current knowledge 
we can hardly predict it. Intravenous thrombolysis treatment has positive outcome only 
in 33-35% of patients and is provoking symptomatic intracranial hemorrhage in 6-8%. 
Similarly, only 36% of those who have undergone mechanical thrombectomy will be 
completely independent in their daily living, moreover, bleeding complications will 
occur in 2.5%. Studies that enhance our knowledge of certain factors regarding the 
tendency of thrombi to recanalize can make great efforts in the future to improve 
therapy. Understanding the changes in certain hemostasis factors under thrombolytic 
therapy is an opportunity to use biomarkers for the early detection of patients with 
worse prognosis in addition to knowing the pathomechanism.   
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Literature overview 
 
 
Overview of the hemostasis system 
The model described by MacFarlane, Ratnoff and Davie in 1964, which emphasized the 
cascade-like activation of coagulation, has now been replaced by the cell-based model 
described by Hoffman and Monroe in 2001. This model breaks down the coagulation 
pathway into three overlapping portions: an initiation phase on cells carrying tissue 
factor, in which only a small amount of active coagulation protein is generated, the 
amplification phase during which the platelet and cofactor activation occurs, in the 
interest of high thrombin generation, and the propagation stage on the surface of 
activated platelets, in which large amounts of thrombin and fibrin clot are formed. 
At the beginning of coagulation, von Willebrand factor (VWF) binds to subendothelial 
matrix proteins, such as type I, III and VI collagen, and the bound VWF binds to the 
GP-Ibα receptor of circulating platelets initiating the process of platelet adhesion during 
which platelets are activated. Thrombin cleaves factor VIII from platelet-binding VWF-
FVIII complex, thereby activating it (FVIIIa). FVIIIa serves FIXa as a cofactor on the 
surface of activated platelets, their complex converts FX to active FX (FXa). 
 
Summary of fibrinolysis 
The blood clot resulting from the coagulation process would inhibit the local blood flow 
after tissue healing and therefore it needs to be demolished. The fibrinolytic system is 
responsible for the localized, timely demarcation of the fibrin clot, the central protease 
of which is plasmin. Plasmin, generated from plasminogen by plasminogen activators, 
is a single-chain glycoprotein. As a first step in fibrinolysis, plasminogen binds to and 
activates the lysine residues on the fibrin surface. The resulting serine protease plasmin 
cleaves the fibrin clot into partially degraded fibrin, generating various, ever-smaller 
fibrin degradation products. D-dimer consists of two D-regions of the fibrin monomer, 
which is covalently linked to the γ chain, which may complex with the E fragment via 
non-covalent binding. Plasminogen activators include tissue-type plasminogen 
activator (t-PA) and urokinase plasminogen activator (u-PA).  
Although the thinner fibrin fibers are degraded faster, fibrin clot consisting of thin fibrin 
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fibers, is more compact and therefore degraded more slowly than the loose clot 
consisting of thicker fibrin fibers. In the case of high thrombin concentrations, the 
formation of denser, thinner fibrin fibers, which is associated with increased risk of 
thrombosis is observed. At low thrombin concentrations a clot of thicker fibrin fibers 
with a looser structure and a higher risk of bleeding is arisen. 
Inhibitors of fibrinolysis 
Fibrinolysis is regulated at several levels. One of the central elements of regulation is to 
prevent plasminogen and t-PA from binding to fibrin C-terminal lysine. The main 
inhibitor of plasmin is α2-plasmin inhibitor (α2-PI). α2-PI is incorporated into the fibrin 
clot to effectively protect the forming clot against fibrinolysis. This is very important in 
inhibiting premature fibrin degradation. 
The major plasminogen activator inhibitor is serpin-type plasminogen activator 
inhibitor-1 (PAI-1). It blocks both t-PA and u-PA. Because of the predominance of PAI-
1, t-PA is mainly present in the circulation as a t-PA-PAI-1 complex. 
 
The role of endothelium in hemostasis, endothelial damage 
and markers 
 
The vascular endothelium provides an antithrombogenic environment by regulating 
coagulation, platelet adhesion, vessel tone and blood flow. The endothelium is 
heterogeneous, it has varying structures and functions depending on tissue and vessel 
type and the diameter of the vessel. The subendothelial surface is rich in collagen, 
heparan, von Willebrand factor and tissue factor, but their amount differs according to 
tissue type. Subcellular organelles of the endothelial cells, the Weibel-Palade bodies, are 
controlled by an appropriate stimulus to release their contents in inflammatory 
processes, when hemostasis is activated, during regulation of angiogenesis, and changes 
in rheological conditions. For the diagnosis of activated endothelium, both ultrasonic 
tests and measurements of different biomarkers (e.g. VWF) are used. 
 
Characterization and pathophysiology of FVIII and VWF 
Biochemistry of FVIII 
The plasma concentration of FVIII is about 1 nM (100-250 ng / mL) and it has a half-
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life of about 12 hours. FVIII is probably synthesized in hepatocytes and/or 
reticuloendothelial systems, but it can also be found in α-granules of platelets. In the 
circulation, it forms a 1:1 complex with VWF via non-covalent binding. However, the 
plasma concentration of VWF is approximately 50 times higher than that of FVIII. 
Approximately 2% of the FVIII circulates in a free form. The plasma FVIII and VWF 
levels are influenced by the blood type (zero-blood type causes 25% lower plasma 
concentration as compared to non-zero blood type), race (about 20% higher levels in 
African Americans than in the Caucasian population) and age (their levels elevating 
with aging. FVIII is activated by limited proteolysis. Its main activator is thrombin, 
followed by FXa, FXIa and FVIIa. VWF not only prolongs FVIII half-life and stabilizes 
its structure but also regulates its activity: VWF prevents FVIII from binding to 
phospholipids and activated platelets, moreover it protects FVIII from activation by 
FXa and from inactivation by APC. The VWF-FVIII complex binds to the injured 
subendothelium in the initial step in the coagulation process, it not only allows the 
adhesion and aggregation of platelets, but also locally increases the FVIII concentration 
so that FVIII can bind to the phosphatidyl serine of activated platelets.  
 
Biochemistry of the VWF factor 
VWF is one of the largest circulating multimeric glycoproteins. VWF is synthesized by 
endothelial cells, megakaryocytes and platelets. The VWF is stored in the Weibel-
Palade bodies of endothelial cells and in the α-granules of platelets. Weibel-Palade 
bodies can secrete VWF and its propeptide both luminally, into the plasma and 
abluminally into the subendothelial matrix. From the Weibel-Palade bodies, VWF is 
secreted into the plasma in ultralarge-multimer form. Subsequently, the ultralarge VWF 
multimer remains bound to the endothelial cell surface. As a result of higher shear 
forces along the vascular wall, the VWF structure changes, becomes elongated, and the 
VWF proteolytic cleavage site on the A2 domain becomes available and is rapidly 
cleaved by the ADAMTS13 metalloprotease. If the highly thrombogenic ultralarge 
VWF multimer is secreted directly into the bloodstream, platelets spontaneously 
aggregate, resulting in thrombosis. 
VWF plasma concentration is ~10 μg/mL, its half-life is 12 hours. The free propeptide 
has a plasma concentration of ~1 μg/mL, with a half-life of 2-3 hours. People with 
blood group A, B and AB have a VWF antigen level ~25% higher than people with zero 
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blood group. According to the literature, plasmin is involved in the shear force 
dependent degradation of VWF beside ADAMTS13. 
 
Increased levels of FVIII and VWF in different pathologies 
The reason for the persistent increase in FVIII and VWF levels is largely unknown, and 
the rate of contribution of the underlying genetic and acquired factors is not entirely 
clear. Several studies suggest that inherited factors play a more pronounced role in the 
determination of plasma levels of both parameters. It is important to note that both 
FVIII and VWF are positive acute phase proteins, i.e. their levels increase by more than 
25% when the immune system is activated. IL-6, the central cytokine of the acute phase 
reaction, is responsible for elevation of FVIII level and IL-6, IL-1β and TNF-α 
cytokines are responsible for VWF level increase. The elevated levels of FVIII and 
VWF have also been associated with the development of certain diseases and their 
prognosis. 
 
Association of increased FVIII and VWF levels and venous and arterial thrombosis  
Several studies have investigated the relationship between venous and arterial 
thrombosis and elevated levels of FVIII and VWF. It was first described by Leiden 
Thrombophilia Study (LETS) more than 20 years ago that elevated FVIII activity and 
VWF antigen levels, as well as non-zero blood group, are risk factors for venous 
thromboembolism. However, after multivariate analysis, only elevated FVIII activity 
remained a significant independent risk factor suggesting that VWF antigen levels 
contributed to the risk by regulating FVIII plasma levels. The relationship between 
elevated FVIII levels and thromboembolic events was subsequently confirmed in a 
number of case-control studies and similar odds ratio of 6.2 times higher thrombosis 
risk were reported as in LETS, in case of values over the reference range. Increased 
FVIII levels have been shown to be a risk factor for recurrent venous thromboembolism 
as well. FVIII levels have increased the risk of venous thromboembolism in several 
studies in a dose-response manner. Several studies have demonstrated that elevated 
FVIII activity combined with other thrombotic risk factors (e.g. oral anticoncipient, FV 
Leiden mutation, malignancy) results in a much higher thrombosis risk than expected 
for a simple additive model, assuming synergistic effects. Vormittag et al. draw attention 
to the fact that elevated levels of FVIII in tumor patients are independent risk factor for 
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venous thromboembolism. In the study of thrombogenic effects of elevated FVIII 
levels, various in vitro and in vivo experimental results demonstrated that elevated 
FVIII associated with increased thrombin generation may be responsible for high risk of 
thrombosis. To a lesser extent, other mechanisms may also contribute to the increased 
risk of thrombosis: there is a direct inverse relationship between plasma FVIII levels 
and APC resistance. 
The relationship between VWF levels and the formation of venous thromboembolic 
disorders is less clear than for elevated FVIII levels, several controversial reports have 
been made on this subject. In some of the publications, instead of elevated VWF levels, 
only the associated FVIII levels could be justified as an independent risk factor. In a 
large population prospective study (LITE: Longitudinal Investigation of 
Thromboembolism Etiology), however, VWF's independent risk role was demonstrated 
for venous thromboembolism: the risk ratio represented by VWF levels in the highest 
quartile was 4.6. 
Compared to venous thromboembolism a lot more studies have investigated the 
relationship between VWF levels and cardiovascular diseases. According to literature 
data, elevated VWF levels have a significant correlation with the size of atherosclerotic 
plaque in the coronary artery. Clinical studies have shown that VWF levels are higher in 
patients with acute myocardial infarction compared to controls. Those with vascular 
disease and elevated VWF levels have higher risk of future myocardial infarction. 
Several studies have found correlation between elevated VWF and FVIII levels and 
increased risk of cardiovascular disease. According to a number of research, VWF may 
indicate an increased risk of micro- and macrovascular complications (e.g. nephropathy, 
cardiovascular disease) in diabetes mellitus type I and II. In the relationship of elevated 
VWF levels and arterial thrombosis, the effects of high shear forces on VWF play a 
central role. Severe degrees of stenosis caused by atherosclerotic plaques in arteries has 
been associated with altered hemodynamic conditions and high shear forces where the 
VWF creates an important link between the platelet membrane glycoproteins and the 
subendothelium. High shear forces increase the release of VWF from the endothelium, 
which increases the risk of thrombus formation. 
Compared to cardiovascular research, far fewer studies address the role of elevated 
FVIII and VWF levels in cerebrovascular diseases. The risk factors and 
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pathomechanism of coronary diseases and ischemic stroke are largely the same, and 
therefore, it can be hypothesized that elevated FVIII/VWF levels play a role in the risk 
of ischemic stroke. A significant part of the publications describe a positive correlation 
between high VWF levels and ischemic stroke risk. In a meta-analysis of 2532 patients, 
there was a minor but significant correlation between increased levels of VWF and the 
risk of ischemic stroke (OR: 1.55, 95% CI: 1.31-1.83), which was, particularly 
considerable in case of atherosclerosis involving major arteries. The association 
between stroke outcome and FVIII/VWF levels have been much less studied, but most 
of them have drawn attention to the relationship between high VWF levels and 
increased mortality.  
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Atrial fibrillation 
Epidemiology 
Atrial fibrillation is the most common persistent arrhythmia, affecting about 33.5 
million people worldwide, with an estimated lifetime risk of 22-26%. Its prevalence is 
expected to double by 2050, largely due to the aging society. 
Risk Factors for Atrial Fibrillation 
Age is considered to be one of the most significant risk factors for atrial fibrillation. 
More than 70% of patients with atrial fibrillation are over 65 years old. Further risk 
factors for atrial fibrillation include physically inactive lifestyle, extreme physical 
activity, both prior and current smoking, alcohol consumption, obesity, diabetes mellitus 
and left-ventricular hypertrophy. Hypertension is considered to be an extremely 
important risk factor for atrial fibrillation. 
Pathophysiology 
The central factor of atrial fibrillation is very fast, unmanaged atrial activity, which can 
be arisen in two ways. On the one hand, it can be derived from one or more rapidly 
discharging nodules that cause irregular driving and atrial fibrillation in the rest of the 
atrium. On the other hand, it can be created by re-entry. For the production of atrial 
fibrillation, a trigger mechanism is required, usually focal spontaneous discharge, most 
commonly in the area of the pulmonary veins. Atrial fibrillation is maintained by 
structural remodelling, which may be caused by a neurohormonal effect (autonomous 
overweight and overactive thyroid function), aging, myocardial ischemia, hypertension, 
obesity or atrial fibrillation. Atrial reestablishment leads to changed ion currents 
(decreased Ca2+ and increased K+ currents down- and upregulation), faster atrial rhythm 
and reduced action potential. As the time progresses, pulmonary fibrillation becomes 
more persistent and becomes more resistant to therapy. 
Virchow’s Triad 
Changes in atrial fibrillation meet the mechanisms described in Virchow’s Triad for 
thrombogenesis, discussed in more detail below, but it is important to note that 
knowledge of the exact pathomechanism of enhanced thromboembolic risk requires 
further research. Virchow’s Triad consists of the following elements: 1/ endothelial or 
endocardial dysfunction (and related structural changes), 2/ abnormal stasis, 3/ 
abnormal coagulation, platelet and fibrinolysis. 
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The presence of endothelial damage in atrial fibrillation is supported by several 
pathophysiological processes and biomarkers. Rheological changes in atrial fibrillation 
and the reduced contraction of the wall of the left atrium, result in reduced NO synthesis 
of the left atrial endothelium. A further clinical sign of endothelial impairment is a 
reduced flow-induced dilation observed in atrial fibrillation patients. In atrial 
fibrillation, inflammatory processes associated with endothelial dysfunction are also 
directly related to thrombus formation. CRP and IL-6 increase the production of 
monocyte tissue factor in vitro. IL-6 increases platelet count and platelet sensitivity to 
thrombin. IL-6 also stimulates fibrinogen transcription. 
Structural and functional left atrial changes observed in atrial fibrillation cause slow 
flow conditions and stasis in the left atrium. Increased hematocrit levels due to wall 
motion abnormalities and hemoconcentration in some patients promote stasis. Atrial 
fibrillation promotes the development of progressive left atrial dilatation and thus stasis. 
Left atrial dilation contributes to thrombogenicity, the size of the left atrium corrected to 
body surface is an independent risk factor for stroke. Thrombus is detected in the left 
atrium or in the left atrial appendage in about 10% of patients with atrial fibrillation. 
The structure of the left atrial atrial appendage, its narrow ostium, and the changes in 
the diameter of the atrium are particularly prone to the formation of stasis as well. In 
case of thromboembolism, more than 90% of the emboli origins from the left atrial 
appendage in non-valvular atrial fibrillation. In transesophagal echography (TEE) stasis 
appears as spontaneous echo contrast (SEC). In atrial fibrillation, the SEC calls 
attention to the increased risk of thromboembolism. Researches have shown that SEC 
has a positive correlation with prothrombin fragment 1+2 (F1+2), fibrinopeptide A and 
TAT complex levels.  
There are a number of reports available on the activation of coagulation cascade in atrial 
fibrillation investigating mainly peripherial blood samples, but fibrinolytic activity in 
patients with atrial fibrillation has been less studied. In most studies investigating the 
pathophysiology of increased thromboembolic risk observed in atrial fibrillation, mainly 
endothelial cell damage markers, inflammatory markers, prothrombotic markers and 
plasmatic markers of platelet activation were investigated. Various clinical studies found 
a correlation between atrial fibrillation and elevated F1+2, TAT complex, fibrinogen 
levels and markers of endothelial dysfunction such as soluble thrombomodulin (sTM) 
and VWF levels. 
Of the markers indicating the activation of hemostasis, most data relating to D-dimer 
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associated with predicting stroke risk in atrial fibrillation. Taking into account the 
clinical risk factors, elevated D-dimer levels are prognostic for stroke risk in non-
valvular atrial fibrillation in patients receiving oral anticoagulant therapy. Wan et al. 
reported in their meta-analysis, that D-dimer could be useful as a prognostic marker for 
left atrial thromboembolism in atrial fibrillation patients as higher D-dimer levels were 
found in spontaneous echo contrast and even higher values for TEE-confirmed left atrial 
thrombus. Clinical studies suggest that VWF levels may also be useful as elevated VWF 
level may indicate an increased risk of left atrial appendage thrombus in atrial 
fibrillation. In the Rotterdam study, there was a positive correlation between plasma 
VWF levels and atrial fibrillation, which was particularly pronounced among women.  
The few studies examining the relationship between atrial fibrillation and fibrinolytic 
system have yielded controversial results. Some studies found elevated levels of PAI-1 
indicating hypofibrinolysis, while other studies suggested elevated levels of t-PA and 
PAP complexes leading to hyperfibrinolysis. However, other studies found no change or 
reduced levels of PAP complex and PAI-1. According to some studies, the background 
of elevated levels of t-PA and PAI-1 found in atrial fibrillation may be associated with 
endothelial dysfunction, inflammation and vascular disease. Abnormal changes in the 
fibrinolytic system can be related not only to thrombus formation, but also to the 
structural transformation of the atrium as it has strong relationship with extracellular 
matrix turnover. In patients with atrial fibrillation, unfavorable structural changes in the 
fibrin clot have also been demonstrated by Drabik et al. According to their results, the 
fibrin clot consisted of more compacted and thinner fibrin fibers detected in patients 
with paroxysmal and persistent atrial fibrillation leading to hypofibrinolysis which 
contributes to thromboembolism. 
Instead of investigating peripheral blood samples, the examination of intracardiac blood 
samples deserves more attention because prothrombotic changes may only occur 
locally, in the intracardiac environment, without these abnormalities being manifested in 
the peripheral circulation. This could be assumed on the basis of earlier studies that 
have shown that prothrombotic changes are limited to the intracardiac environment in 
atrial fibrillation. However, probably because of the difficult collection of intracardiac 
blood samples, in the last decade, only a few studies have been investigating the 
hemostasis system from left atrial samples in atrial fibrillation. Publications 
investigating left atrial blood samples so far have only studied selected members of the 
hemostasis system (VWF, P-selectin, TAT complex, platelet factor 4, platelet-derived 
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sCD40), furthermore the fibrinolytic system has been less studied in this regard. We did 
not find any data in the literature regarding FXIII and α2-PI, two key members of 
fibrinolysis, investigated in intracardiac blood samples. In most studies investigating 
intracardiac blood samples, the atrial fibrillation patient group was not compared to age 
and sex adjusted non-atrial fibrillation control group. In many studies investigating 
intracardiac blood samples, patients had received non-fractionated heparin prior to 
sampling, which had a major influence on the hemostasis system, thus limiting the 
parameters of hemostasis that could be investigated. Examination of blood samples 
from the left atrial appendage investigating hemostasis and fibrinolysis parameters is 
also rare in the literature, despite the fact that earlier clinical studies indicate that 
thrombus located in the left atrial appendage is the most common source of embolism, 
making it the most potent thrombogenic intracardiac area in atrial fibrillation. 
Diagnosis 
Atrial fibrillation is often asymptomatic or patients present non-specific symptoms: 
palpitations, fatigue, dizziness, dyspnea, chest pain and syncope. The severity of the 
symptoms can be estimated with the EHRA (European Heart Rhytm Association) 
scoring system. The diagnosis is usually based on a 12-lead ECG but in the case of 
paroxysmal cases the arrhythmia is not always detectable. In this case 24-hour Holter 
monitoring can be useful. 
Classification 
Atrial fibrillation can be divided into five groups (first diagnosed atrial fibrillation, 
paroxysmal, persistent, long standing persistent, and permanent atrial fibrillation 
groups) based on the existence and frequency of arrhythmia. 
Therapy 
Stroke prevention 
Atrial fibrillation have increased mortality and morbidity as a result of increased 
thromboembolic complications and increased stroke risk. Prevention of stroke plays a 
central role in the treatment of atrial fibrillation, as stroke risk is increased fivefold in 
patients with atrial fibrillation. To assess the risk of stroke, various clinical scoring 
systems can be used to assist in therapeutic decision making. According to the latest 
recommendations, an improved version of the CHADS2 scale, the CHA2DS2-VASc 
scoring system is most suitable for assessing stroke risk, taking risk factors into account 
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in weighted terms. 
In the case of low stroke risk (0 point in men, 1 point in women) no antithrombotic 
therapy is required. For higher values, vitamin K antagonist or novel oral anticoagulant 
(NOAC) is recommended. Vitamin K antagonist (VKA) reduces stroke risk by 64% and 
total mortality by 26%. In contrast, the use of antiplatelet therapy reduces stroke risk by 
22% and does not significantly reduce total mortality. The latest European guidelines 
recommend NOAC therapy instead of VKA therapy, based on the overall effect of 
NOAC. 
Catheter ablation 
Catheter ablation is indicated in case of non-tolerated or unsuccessful antiarrhythmic 
drug therapy when treating paroxysmal, persistent and long standing persistent atrial 
fibrillation. Catheter ablation is the first line therapy for symptomatic paroxysmal atrial 
fibrillation. 
Professional guidelines for catheter ablation interventions have changed regarding 
periprocedural anticoagulant therapy in recent years. The 2008 and 2010 guidelines 
have suggested that oral anticoagulant therapy should be suspended before catheter 
ablation, before the day of intervention and during the procedure heparin administration 
is recommended. The latest guideline does not recommend the suspension of oral 
anticoagulants, but suggest that thrombosis prophylaxis should be continued before 
catheter ablation (VKA/NOAC), during ablation (heparin) and after the procedure 
(VKA/NOAC) because of increased periprocedural thromboembolic risk. According to 
these latest guideline, oral anticoagulation is recommended for at least 2-3 months after 
the intervention. Thereafter, the need for continued therapy should be judged based on 
stroke risk (CHA2DS2-VASc: ≥1 for men and ≥2 for women). 
Prognosis 
Odutayo et al. examined 104 cohort studies and a total of 587867 patients with atrial 
fibrillation in their meta-analysis. According to their results, atrial fibrillation is 
associated with an increased risk of the following diseases and conditions: all-cause 
mortality, major cardiovascular events, ischemic stroke, ischemic heart disease, sudden 
death, heart failure, chronic kidney disease, peripheral arterial disease. 
Atrial fibrillation and biomarkers 
Biomarker research in atrial fibrillation can be significant in many ways: on the one 
hand, they can contribute to a better understanding of the various pathophysiological 
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mechanisms and the possible complications, on the other hand biomarkers can be useful 
tools for risk assessment of various complications. According to some 
recommendations, the addition of biomarkers (pro-BNP, hs cardial troponin, D-dimer, 
IGDF-15: inflammatory growth differentiation factor-15, micro-RNAs, galectin-3, CRP, 
creatinine, cystatin c) to clinical stroke risk scales may further refine their clinical value. 
According to Roldan et al. the addition of VWF levels to CHA2DS2-VASc and HAS-
BLED scales may further increase their prognostic value. 
 
 
Stroke 
Epidemiology 
According to the literature, stroke is considered to be the second most common cause of 
death and the most common cause of disability worldwide. Between 1990 and 2010, the 
incidence of stroke across the world increased by 68% and the death rate by 26%. The 
incidence of ischemic stroke during this period increased by 37% and its mortality by 
21% worldwide. 
Definition, subtypes 
Acute stroke is a brain, retina or spinal cord focal dysfunction that lasts for more than 
24 hours or longer if imaging procedures (CT or MRI) or autopsy can verify focal 
infarction or hemorrhage. In the case of transient ischemic attack (TIA), focal 
dysfunction lasts less than 24 hours, and infarction cannot be confirmed by imaging 
procedures. Within the five major groups of stroke (ischemic stroke, hemorrhagic 
stroke, subarachnoid hemorrhage, cerebral venous thrombosis, spinal ischemic or 
hemorrhagic stroke) further subgroups can be distinguished. The origin of ischemic 
stroke is usually multifactorial, so the ideal classification system should include the 
most likely etiologic and pathophysiological mechanisms. The etiologic scales include 
the most commonly used TOAST (Trial of ORG 10172 in Acute Stroke Treatment, large 
artery atherosclerosis, cardioembolism, small vessel occlusion, other known etiology, 
unknown etiology) published in 1993. In the 21 to 37% of cases of ischemic stroke, 
there is a cardioembolic source, in 15-48% atherothrombotic cause, in 10-34% small 
vessel disease, and in 30-38% unknown etiology. Of these, the worst outcome is 
expected for the cardioembolic type, with the highest mortality rate in the hospital (6-
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27%). Studies have shown that collateral circulation is better in atherothrombotic stroke 
than in cardioembolic stroke, which can contribute to a less favorable outcome in case 
of cardioembolic stroke, as collateral circulation plays a significant role in the success 
of reperfusion therapies as well as in long-term outcome. 
Risk factors 
The risk of both ischemic and hemorrhagic stroke is increased in advanced age (for 
patients older than 75 years, the relative risk of stroke is fivefold compared to 55-64 
years of age), hypertension (in case of 160/95 mm Hg blood pressure the relative risk of 
stroke is seven times higher compared to 120/80 mm Hg), smoking (the relative risk of 
active smokers is double) and diabetes mellitus (the relative risk of stroke is double). 
The risk factors for hemorrhagic stroke include excessive alcohol consumption, 
thrombolytic, anticoagulant, and antiplatelet therapy. Stroke risk factors include male 
sex, but more women being affected by stroke due to the fact that women have longer 
life expectancy. Obesity and dyslipidemia also increase the risk of ischemic stroke 
(primarily raising the risk of large artery disease). Ischemic heart disease is a triple 
relative risk of stroke, whereas heart failure, atrial fibrillation and previous TIA have a 
five-fold relative risk. Inflammation, infection, migraine with aura and oral 
contraceptives also increase the risk of stroke. Increased VWF levels contribute to the 
increased risk of cardioembolic stroke, elevated leukocyte increase the risk of lacunar 
stroke, and hyperhomocysteinemia may increase the risk of large artery disease. 
Diagnosis 
Typical stroke symptoms include sudden, half-side numbness, paralysis, loss of vision, 
altered speech, ataxia, and non-orthostatic dizziness. Typical symptoms summed up in 
the FAST campaign for the general public for easy recognizability and quick care: facial 
weakness, arm weakness, speech problems, calling emergency services. The purpose of 
diagnostic procedures is to identify the stroke subtype, to determine its localization, to 
exclude other stroke imitating diseases. To do this, the following information should be 
obtained first: time of symptoms onset, blood pressure and blood glucose measurement 
at hospital admission, determination of severity of the stroke by NIHSS (National 
Institute of Health Stroke Scale) and brain imaging procedures: primarily non-contrast 
CT, which is used to detect ischemic and hemorrhagic stroke and to detect early 
ischemic signs and arteriosclerosis. Multimodal CT (CT perfusion, CT angiography, CT 
venography) can provide information on the extent of ischemic injury, perfusion status, 
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vascular stenosis/occlusion, collateral flow and acute stroke differential diagnosis, 
furthermore intracranial hemorrhage can be excluded by multimodal CT. 
With NIHSS, beyond the severity of stroke, stroke progression, response to therapy, 
short and long term outcome can also be estimated. NIHSS examines the level of 
alertness, eye movements, field of vision, the function of facial muscles (paralysis), the 
motoric function of the hands and feet, coordination (presence of ataxia), sensory 
function and speech (presence and extent of aphasia). Its benefits include its validity 
and reliability, also when performed by non-neurologist specialists. It is widely used in 
clinical trials. 
The ASPECT (Alberta Stroke Program Early CT) score was developed and validated for 
systemic detection and quantification of early ischemic changes in CT on the territory of 
middle cerebral artery. On the 10-point scale, the value of 10 means the normal state. 
Clinical research shows that ASPECT score is independently associated with long-term 
functional outcome. The ASPECT value ≤7 has a strong correlation with poor functional 
status (modified Rankin scale: mRS ≥3) and the increased risk of intracerebral 
hemorrhage. A separate ASPECT score was created and validated for the basilar artery 
territory (pc-ASPECT: posterior circulation Alberta Stroke Program Early CT score). 
According to research, the pc-ASPECT <8 value independently predicts poor functional 
outcome (mRS ≥4), despite the complete revascularization. The ASPECT score is 
widely used in clinical trials, it is considered as a useful diagnostic tool, but it is not 
recommended to determine patient prognosis or to exclude patients from a therapeutic 
procedure based on ASPECT score. 
To evaluate the long-term functional status after acute stroke, the modified Rankin scale 
is widely used. On the scale of 0 to 6, mRS evaluates global functional status with a 
focus on mobility. MRS is not only used in everyday clinical practice, but is also used in 
clinical trials, e.g. when comparing the outcome of different study groups. The strengths 
of validated mRS include comprehensive measurement of functionality and having 
good correlation with lesion size, stroke type, neurological damage and other functional 
test measurements. At the same time, its subjectivity and reproducibility are considered 
to be weak. 
Therapy 
Intravenous thrombolytic therapy with alteplase initiated within 4.5 hours of symptom 
onset is considered standard specific treatment for acute ischemic stroke if the patient 
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meets the criteria for inclusion. Dose of intravenous alteplase (iv. rt-PA: recombinant 
tissue-type plasminogen activator) is 0.9 mg/kg which does not exceed 90 mg. 10% of 
the dose should be administered as a bolus and the remaining for 60 minutes as an 
infusion. The best results can be achieved by thrombolysis within the first 90 minutes of 
symptom onset. Thrombolytic therapy should be monitored for 24 hours and the 
patient's blood pressure should be monitored (below 180/105 mm Hg) as well. The 
safety and efficacy of rt-PA therapy was supported by several clinical studies and 
systematic summary reports, but less than half of the patients treated in this way 
achieved functionally independent status three months later with full or nearly complete 
recovery of neurological functions. The most serious complication of thrombolytic 
therapy is intracerebral hemorrhage, which occurs more frequently in large ischemia, 
older age, more serious stroke indicated by NIHSS, hyperglycemia, atrial fibrillation, 
congestive heart failure and renal insufficiency. Intracerebral hemorrhage occurs in 
approximately 7% of patients treated with rt-PA thrombolysis, significantly increasing 
morbidity and mortality. Although many risk factors for the adverse outcome of 
thrombolysis with rt-PA have been identified (e.g. old age, male gender, stroke severity, 
diabetes mellitus, hyperglycemia diagnosed at hospital admission), it is not easy to 
predict the outcome before thrombolysis, due to the fact that most risk assessment 
scales based on clinical and radiological data are not specific and have a moderate 
predictive value. 
Mechanical thrombectomy is another novel option in the treatment of ischemic stroke 
within the first 6 hours. Thrombectomy can be applied after thrombolytic therapy in 
patients eligible for intravenous thrombolysis, as well as in patients who may not be 
eligible for intravenous thrombolysis due to increased bleeding risk. 
Intraarterial thrombolysis therapy may be used within 6 hours after symptom onset in 
patients with large artery occlusion, in patients who are not eligible for iv. rt-PA therapy 
due to anticoagulant therapy or postoperative status, and in patients after iv. 
thrombolysis without any improvement. 
Initial therapies for acute ischemic stroke prior to thrombolysis include reducing blood 
pressure below 185/110 mm Hg to avoid hemorrhagic complications of thrombolytic 
therapy. Treatment of hyperglycemia is also required, as clinical studies have indicated 
that >7.7 mmol/l blood glucose levels have associated with worse long-term outcome. 
24 hours after hospital admission, control brain imaging (CT or MRI) is required to 
exclude hemorrhage and determine radiological changes that can help estimate 
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outcome. 
Prognosis 
The mortality of acute stroke is 15% after one month, 25% after one year and 50% after 
five years. 40% of stroke survivors have unfavorable functional outcome (mRS 3-5). 
The risk of stroke recurrence after ischemic stroke or TIA is 10% one week later, 15% 
one month later, 18% three months later, 10% one year later and 25% five years later. 
The risk of recurrence is greater in case of symptomatic atherosclerosis, vascular risk 
factors, active thrombosis sources and suspension of antiplatelet or antihypertensive 
therapy. In patients with atrial fibrillation the risk of stroke recurrence increases with the 
increase in CHA2DS2-VASc and ABC score. 
Stroke biomarkers 
To improve acute stroke treatment, it would be helpful to supplement risk assessment 
scales based on clinical and radiological data with biomarkers. 
FVIII and VWF as stroke biomarkers 
Several studies confirmed the role of FVIII and VWF in the pathophysiology of acute 
ischemic stroke. In animal experiments, plasma levels of FVIII and VWF showed direct 
correlation with the rate of formation of arterial thrombus and the extent of ischemia. 
Human research has shown that elevated levels of FVIII and VWF increase the risk of 
stroke. Elevated levels of FVIII increased the risk of stroke with atherothrombotic and 
cardioembolic etiology. However, there is much less information regarding the 
relationship between FVIII and VWF levels and the outcome of stroke. There was a 
significant association between low rate of recanalization and adverse outcome and 
elevated VWF levels following the therapy of acute myocardial infarction thrombolysis. 
Changes in the levels of FVIII and VWF during acute stroke thrombolytic therapy are 
less known, although experimental results on animal models suggest that FVIII 
degradation during thrombolysis may have a causal effect on bleeding complications. 
In the past decades particular attention is drawn for the feasibility of VWF inhibition 
therapy for acute stroke. VWF antagonists used in combination with rt-PA may 
contribute to the lysis of thrombus and may limit the formation of consequent thrombo-
inflammatory ischemia or reperfusion injury. The principle of VWF inhibition therapies 
is based on animal experiments which found that the inhibition of GPIb-VWF and 
VWF-collagen interaction are protective against the onset of ischemic brain damage in 
mice with acute stroke. According to the literature, platelets and VWF contribute to the 
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development of neurological lesions not only through the initiation of thrombus 
formation but also through the activation of inflammatory processes. The role of VWF 
is also supported by experimental results with ADAMTS13 metalloprotease. According 
to clinical observations, low ADAMTS13 activity was associated with higher risk of 
ischemic stroke. In animal experiments, use of recombinant ADAMTS13 showed a 
protective effect against reocclusion, reduced leukocyte migration to the site of injury 
and reduced bleeding complications of rt-PA therapy by the preservation of the blood-
brain barrier. Given that most of these researches have been based on animal models, 
human studies on FVIII and VWF levels may provide important findings.  
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Objective 
 
 
In the course of our work, two observational clinical studies were performed to 
investigate the correlation between FVIII and VWF levels and other hemostasis factors 
and the pathomechanism of increased thromboembolic risk in patients with atrial 
fibrillation, and to investigate the correlation between FVIII and VWF levels and the 
outcome of therapy after thrombolysis in patients with acute ischemic stroke. 
 
In detail: 
1. We aimed to identify local hemostasis and fibrinolysis abnormalities, which are 
associated with AF and increase the risk of thromboembolism. Intracardiac 
blood samples taken from the left atrium and left atrial appendage of AF patients 
and non-AF controls were tested for a comprehensive set of hemostasis and 
fibrinolytic factors in order to assess AF associated alterations. 
2. We aimed to investigate the relation of FVIII and VWF levels to stroke severity 
and stroke etiology. Furthermore, we aimed to investigate FVIII and VWF levels 
during the course of thrombolysis in acute ischemic stroke (AIS) patients and to 
find out whether they predict long-term outcomes. 
 
  
 22 
Patients and Methods 
 
Intracardiac Hemostasis and Fibrinolysis Parameters in 
Patients with Atrial Fibrillation 
Study Population 
Consecutive patients undergoing radiofrequency ablation for symptomatic paroxysmal 
or persistent AF (AF group) as well as age- and sex-matched patients with any 
arrhythmia other than AF requiring left atrial access (non-AF control group) were 
enrolled in the study. Patients were enrolled between 2013 October and 2015 December. 
All AF patients were undergoing pulmonary vein isolation (PVI) with phased 
radiofrequency (RF) or cryoballoon ablation procedure. Non-AF controls were 
undergoing routine RF ablation of a left atrial substrate (mostly a left-sided accessory 
atrioventricular pathway). 
Inclusion criteria for the AF group were the following: age 18–75 years, documented, 
symptomatic paroxysmal or persistent AF, failure of at least one antiarrhythmic drug, 
and patient being willing to sign a written informed consent. Inclusion criteria for the 
control group were age 18–75 years, documented non-AF arrhythmia including one of 
the following: left atrial tachycardia, paroxysmal supraventricular tachycardia 
(orthodromic or antidromic), or FBI (fast, broad, and irregular) tachycardia due to a left-
sided accessory pathway, preexcitation on the 12-lead electrocardiogram in an 
asymptomatic individual in whom the electrophysiology study revealed a left-sided 
accessory pathway potentially resulting in significant arrhythmia based on its 
conduction properties, and patient being willing to sign a written informed consent. 
Exclusion criteria for the patient and control groups were previous heart surgery, 
valvular heart disease, left ventricular ejection fraction (LVEF) ≤30%, heart failure of 
New York Heart Association functional classification (NYHA) class III or IV, 
documented carotid stenosis, history of ischemic stroke or TIA, prior cardiac surgery, 
unstable angina or myocardial infarction within the last 3 months, severe chronic 
obstructive pulmonary disease, known bleeding or thrombotic disorders, acute 
inflammation, contraindication to oral anticoagulation or to diffusion weighted magnetic 
resonance imaging (DW MRI), and pregnancy. Additional exclusion criteria for the 
patient group were long-standing persistent AF, reversible cause of AF (e.g. 
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hyperthyroidism), and presence of AF thrombus. Risk factors for stroke (hypertension, 
diabetes mellitus, smoking, BMI, etc.) together with the list of current medications were 
assessed before the enrollment of patients.  
 
The CHADS2 score (congestive heart failure, hypertension, age ≥75 years, diabetes 
mellitus, and stroke/transient ischemic attack), CHA2DS2-VASC score (congestive heart 
failure, hypertension, age ≥75 years, diabetes mellitus, stroke/ transient ischemic attack/ 
thromboembolism, vascular disease (prior myocardial infarction, peripheral vascular 
disease, or aortic atherosclerosis), age (65–74 years), and sex category (female)) and 
EHRA score (European Heart Rhythm Association score) were recorded for every AF 
patient.  
The study design was in accordance with the guiding principles of the Declaration of 
Helsinki, and was approved by the Institutional Ethics Committee of the University of 
Debrecen and the Ethics Committee of the National Medical Research Council (ETT-
TUKEB). All patients signed a written informed consent form prior to inclusion.  
Electrophysiology Procedure and Blood Drawing 
Patients were hospitalized 1 or 2 days before the procedure. All medications with a 
potential effect on coagulation or platelet activity were discontinued for a period of at 
least three halflives (or a period needed for reaching complete decay of their action) 
before the procedure. Transesophageal echocardiography was carried out within 24 h 
prior to the procedure in order to rule out the presence of a cardiac thrombus in all AF 
patients. All procedures were carried out under conscious sedation, using midazolam 
and fentanyl. The ablation procedures were performed as described previously. Blood 
samples were taken before the ablation procedures from multiple sites: (1) peripheral 
femoral venous (FV) sheath, (2) left atrial (LA) sheath, and (3) left atrial appendage 
(LAA) sheath. Intracardiac blood samples were collected before the administration of 
unfractionated heparin.  
Briefly, three punctures of the right femoral vein were performed using the Seldinger 
technique and introducers with side arms were placed in the vein. Forty-five ml blood 
sample was drawn through the side arm of a short introducer immediately after access 
to the vein, from which the first 5ml of blood was discarded in order to exclude 
intrasheath hemostasis activation (FV sample). Blood samples were collected into 
vacutainer tubes (tubes anticoagulated with K3-EDTA for complete blood count, tubes 
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containing 0.109 M sodium citrate and CTAD (buffered citrate, theophylline, adenosine, 
and dipyridamole)) for hemostasis and fibrinolysis tests (Becton Dickinson, Franklin 
Lakes, NJ). After blood drawing, a decapolar catheter and an intracardiac echo (ICE) 
catheter were advanced from the femoral vein and positioned in the coronary sinus and 
in the right atrium, respectively. A single ICE-guided transseptal puncture was 
performed using a Mullins transseptal sheath and a Brockenborough needle (Medtronic, 
Kirkland, QC, Canada) under fluoroscopic and ICE guidance using standard technique. 
After crossing the septum, the dilator of the Mullins sheath was removed and 45 ml 
blood sample was drawn from the LA, from which the first 5 ml of blood was discarded 
(LA sample). LA blood samples were collected into vacutainer tubes as described 
above. After the blood drawing of LA samples, the LAA was accessed by using a 5 F 
pigtail catheter (Medtronic, Kirkland, QC, Canada) under fluoroscopy and ICE control. 
A blood sample of 45 ml was taken from the LAA, of which, again, the first 5 ml was 
discarded (LAA sample). LAA blood samples were collected into vacutainer tubes as 
described above. Immediately after blood samplings, 150 IU/kg body weight i.v. 
heparin was administered and ablations were performed according to standard 
protocols. 
Laboratory Investigations 
Blood samples anticoagulated with K3-EDTA were immediately tested for complete 
blood count. Blood samples anticoagulated with citrate or CTAD were centrifuged twice 
at 1500 g at room temperature for 20 min and plasma samples were stored at −70 °C 
until further analysis. The measurement of plasminogen activator inhibitor-1 (PAI-1) 
activity was performed from plasma samples anticoagulated with CTAD; besides this 
measurement, all hemostasis and fibrinolysis tests were performed using citrated 
plasma. Hemostasis and fibrinolysis tests were performed from all sample types (FV, 
LA, and LAA samples). Screening tests of hemostasis (prothrombin time, activated 
partial thromboplastin time, and thrombin time) were performed using routine methods 
(Siemens Healthcare Diagnostic Products, Marburg, Germany). Fibrinogen 
concentrations were measured by the Clauss method. Commercially available ELISA 
tests were used to determine PAI-1 activity (Technozym PAI-1 Actibind, Technoclone, 
Vienna, Austria), plasmin-𝛼�2-antiplasmin (PAP) complex (Technozym PAP complex 
ELISA kit, Technoclone, Vienna, Austria), and thrombin-antithrombin (TAT) complex 
(Enzygnost TAT micro, Siemens Healthcare Diagnostic Products, Marburg, Germany). 
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Factor VIII (FVIII) activity using a chromogenic assay, von Willebrand factor (VWF) 
antigen level, 𝛼�2- plasmin inhibitor (𝛼�2-PI) activity, plasminogen activity and D-dimer 
levels were measured on a BCS coagulometer by standard methods (Siemens 
Healthcare Diagnostic Products, Marburg, Germany). Plasma levels of FXIII activity 
were determined by ammonia release assay using a commercially available reagent kit 
(REA-chrom FXIII kit, Reanalker, Budapest, Hungary). Soluble fibrin monomer levels 
(FM) were measured using the Liatest FM assay (Diagnostica Stago, Asni`eres, France).  
High sensitivity C-reactive protein (CRP) and a comprehensive lipid profile including 
total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein 
(HDL) cholesterol, and triglyceride levels were measured from antecubital vein blood 
samples of all patients upon hospital admission by routine methods (Roche Diagnostics, 
Mannheim, Germany). 
Statistical Analysis 
All data were analyzed using the GraphPad Prism Software version 5.0 (La Jolla, CA) 
and the Statistical Package for Social Sciences (SPSS, Release 22.0, Chicago, IL). 
Normality of the data was evaluated by the D’Agostino and Pearson omnibus normality 
test. A paired t-test or Wilcoxon matched pairs rank-sum test was applied for comparing 
results obtained from intracardiac and FV samples. In case of two-group analyses 
between AF patients and controls, unpaired t-test or in case of nonparametric data 
Mann–Whitney U test was used. ANOVA or Kruskal- Wallis test was applied for 
multiple comparisons. Pearson’s or Spearman’s correlation coefficient was used to 
determine the strength of correlation between variables. Differences between categorical 
variables were assessed by the Fisher’s exact test. P <0.05 was considered statistically 
significant. 
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Elevated Factor VIII and von Willebrand Factor Levels 
Predict Unfavorable Outcome in Stroke Patients Treated with 
Intravenous Thrombolysis 
Patients 
Consecutive AIS patients aged 18 years or more, eligible for thrombolysis, admitted to a 
single Stroke Center (Department of Neurology, Faculty of Medicine, University of 
Debrecen, Hungary) were enrolled in the study. All patients were within 4.5 h of their 
symptom onset at the time of admission. Patient enrollment lasted for 22 months 
starting in March 2011. Intravenous thrombolytic therapy was applied according to the 
European Stroke Organization (ESO) guidelines using rt-PA (Alteplase, Boehringer 
Ingelheim, Germany). Inclusion and exclusion criteria of patients were identical to that 
of thrombolysis eligibility as described in the ESO 2008 guideline. The diagnosis of IS 
was based on clinical symptoms and brain imaging using computer tomography (CT) 
scan and CT angiography (CTA). Admission CTA was used to identify the level of 
vessel occlusion in every patient. A control CT was performed for every patient 24 h 
after thrombolysis. All CT images were analyzed by four different investigators blinded 
to the clinical state of the patients and the Alberta Stroke Program Early CT Scores 
(ASPECTS) were calculated. Neurological deficit of patients was determined by the 
NIHSS at various time points: on admission and at 2 h, 24 h, and 7 days post-lysis. 
Stroke etiology was determined according to the Trial of ORG 10172 in Acute Stroke 
Treatment (TOAST) criteria. Hemorrhagic events were classified as symptomatic or 
asymptomatic intracranial hemorrhage (SICH or aSICH, respectively) according to the 
European Cooperative Acute Stroke Study (ECASS) II criteria.  
For each patient a detailed list of clinical parameters was recorded including 
demographic characteristics, neurological status, time of symptom onset, cardiovascular 
risk factors (arterial hypertension, atrial fibrillation, hyperlipidemia, diabetes mellitus, 
smoking status), history of previous cardiovascular events, and medications.  
Patients were followed and long-term functional outcomes were determined at 90 days 
post-event using the modified Rankin Scale (mRS).  
The following outcomes were investigated:  
(1) short-term functional outcome at 7 days post-event: favorable outcome was defined 
as a decrease in NIHSS score by at least 4 points or to 0 by day 7, unfavorable outcome 
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was defined as an increase in NIHSS score by at least 4 points by day 7.  
(2) The presence of therapy-associated SICH or aSICH was defined according to 
ECASS II criteria.  
(3) Long-term functional outcome at 90 days post-event: poor long-term outcome was 
specified as an mRS greater than 2.  
The study was approved by the Ethics Committee of the University of Debrecen, 
Hungary. All patients or their relatives provided written informed consent. 
Blood Sampling and Laboratory Measurements 
Peripheral blood samples were drawn from patients into vacutainer tubes on three 
different occasions: upon hospital admission (before thrombolysis), immediately after 
the administration of rt-PA infusion (~1 h after the initiation of thrombolysis) and 
approximately 24 h after the administration of thrombolytic therapy. Routine laboratory 
tests were performed from blood samples taken before thrombolysis and included the 
measurements of complete blood count, serum ions, glucose levels, basic kidney 
function tests, liver function test, high-sensitivity C-reactive protein (hsCRP), and 
screening tests of coagulation (prothrombin time, activated partial thromboplastin time 
and thrombin time). Blood samples anticoagulated with sodium citrate, theophylline, 
adenosine and dipyridamole (Vacuette CTAD Tubes, Greiner Bio-One, Austria) were 
centrifuged at 1,220 g, room temperature for 15 min. Plasma aliquots were labeled with 
a code and stored at −70 °C until further analysis of FVIII activity and VWF antigen 
levels. FVIII activity, determined by chromogenic method and VWF antigen level, 
determined by immunoturbidimetric assay were measured from coded plasma samples 
on a BCS coagulometer by standard methods (Siemens Healthcare Diagnostic Products, 
Marburg, Germany). 
Statistical Analysis 
Statistical analysis was performed using the Statistical Package for Social Sciences 
(SPSS, Release 22.0, Chicago, IL, USA) and GraphPad Prism 5.0 (GraphPad Prism 
Inc., La Jolla, CA, USA) softwares. Normality of the data was evaluated by the 
Shapiro–Wilk test. As FVIII activity and VWF antigen levels were not normally 
distributed at any time points measured, the Mann–Whitney U test was applied for all 
two-group analyses and the Kruskal–Wallis analysis with Dunn–Bonferroni post hoc 
test was used for multiple comparisons. Differences between categorical variables were 
assessed by the Fisher’s exact or χ2 test. Friedman’s two-way ANOVA with Dunn–
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Bonferroni post hoc test was applied to investigate the effect of thrombolysis on FVIII 
activity and VWF levels. Strength of association between FVIII activity and VWF 
antigen levels was tested using Spearman’s correlation test. In order to test for 
differences between adjusted means, univariate analysis incorporating covariate testing 
(one-way ANCOVA) was performed after logarithmic transformation of data. Positive 
predictive values (PPVs) and negative predictive values (NPVs) of the studied 
parameters were assessed using contingency tables and the Fisher’s exact test. A binary 
backward logistic regression model was used to determine whether elevated FVIII and 
VWF levels of different time points are independent predictors of poor functional 
outcomes at 90 days post-event. Adjustment of the models were based on the results of 
previous statistical analyses (Mann–Whitney U test, Fisher’s exact, or χ2 test), previous 
literature and methodological principles (dichotomized variables wherever possible). 
Results of the logistic regression analysis were expressed as odds ratio (OR) and 95% 
confidence interval (CI). A p-value of <0.05 was considered statistically significant. 
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Results 
 
Intracardiac Hemostasis and Fibrinolysis Parameters in 
Patients with Atrial Fibrillation 
Baseline Characteristics of AF Patients and Non-AF Controls 
In total 32 AF patients and 18 controls were enrolled in the study. Unfortunately, 8 AF 
patients and 4 controls had to be excluded from the study population due to technical 
problems arising during the intracardiac blood drawing procedure (clot formation in the 
sample during the blood drawing procedure, clot formation on the sheath requiring 
instant heparin administration, etc.). In case of 12 AF patients and 8 non-AF controls an 
LAA sample was not possible to obtain due to technical/anatomic difficulties. The final 
numbers of AF patients and non-AF controls included in the study were 24 and 14, 
respectively. No significant differences were observed between the AF patients and non-
AF controls regarding BMI and cerebrovascular risk factors except for smoking, which 
was more frequent in controls. Only two patients experienced paroxysmal AF periods 
during the procedure. Most AF patients had low or moderate risk for stroke according to 
the CHADS2 and CHA2DS2-VASC score. A similar fraction of AF patients and non-AF 
controls received statins and antihypertensive drugs. CRP levels and lipid parameters, 
measured from peripheral venous blood samples, did not differ significantly between 
AF patients and non-AF controls. 
Intracardiac Levels of Hemostasis Factors in AF Patients and Non-AF 
Controls 
FVIII activity and VWF antigen levels were significantly higher in the AF patient group 
as compared to the control group in the samples obtained from the FV and from the LA. 
LAA levels of both proteins showed a marked elevation in AF patients as well; however, 
very likely due to the lower number of LAA samples, results were only borderline 
significance. Elevated levels were not due to acute phase reaction as CRP levels of all 
individuals were in the normal range. In case of AF patients, median values of VWF 
antigen levels were above the upper limit of the reference interval in all sample types 
(171% (IQR: 129.4–195.1%), 176.7% (IQR: 129.3–192.7%), and 164% (IQR: 114.8–
189.8%) for FV, LA, and LAA sample types, resp.). The observed differences between 
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patients and controls remained significant after adjustments for AB0 blood type in the 
statistical model. No local differences were found in the FVIII and VWF levels of 
intracardiac samples as compared to the FV samples in either group. FVIII and VWF 
levels showed good correlation in AF patients (Spearman 𝑟�= 0.808, 95% CI: 0.691–
0.884, 𝑝� <0.0001) as well as in non-AF controls (Pearson 𝑟�= 0.737, 95% CI: 0.502–
0.871, 𝑝� <0.0001), suggesting that they are in a complex form. No considerable 
differences were seen in the correlation of FVIII and VWF levels with respect to 
sampling sites (data not shown). No significant differences were found between sample 
types and patient groups in case of FXIII activity and fibrinogen levels. 
Intracardiac Levels of Coagulation Activation Markers in AF Patients 
and Non-AF Controls 
Median values of soluble FM and TAT complex levels exceeded the upper limit of 
reference interval in the FV samples of AF patients (18.16 𝜇�g/mL (IQR: 5.83–33.91 
𝜇�g/mL) and 15.17 𝜇�g/L (IQR: 6.96–22.83 𝜇�g/L) for FM and TAT, respectively) and 
non-AF controls (23.05 𝜇�g/mL (IQR: 9.55–51.41 𝜇�g/mL) and 16.36 𝜇�g/L (IQR: 9.84–
28.59 𝜇�g/L) for FM and TAT, respectively). Moreover, both parameters were 
significantly elevated in the samples obtained from the LA as compared to the FV 
samples in case of both groups, suggesting that that the observed differences are not AF-
specific and most probably the catheterization procedure itself has a major effect on the 
results. FM levels showed a decrease in the LAA samples as compared to the LA 
samples; this decrease was significant in case of the patients (𝑝� <0.001, Wilcoxon 
matched pairs rank-sum test). TAT complex levels were also significantly lower in the 
LAA samples versus LA samples of AF patients (𝑝� <0.01, Wilcoxon matched pairs 
rank-sum test), while such significant association was not observed in case of the non-
AF control patients. TAT complex levels were significantly increased in the LAA 
samples of both AF patients and non-AF controls as compared to the FV samples. 
Surprisingly, a marginal but significant elevation was observed in the TAT complex 
levels of the LA samples of non-AF controls versus AF patients (𝑝� <0.05). 
Intracardiac Parameters of Fibrinolysis in AF Patients and Non-AF 
Controls 
Plasminogen activity, 𝛼�2-PI activity, and PAI-1 activity levels showed no difference 
between AF patients as compared to non-AF controls. In general, no difference was 
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observed between the intracardiac and peripheral levels of these parameters, except for 
a small, but significant reduction of plasminogen level in the LAA versus FV sample of 
the AF patients. PAP complex and D-dimer levels were significantly increased in the LA 
samples of both AF patients and non-AF controls as compared to the respective FV 
samples, suggesting that the activation of the fibrinolytic system took place during the 
transcatheter procedure in both groups. In fact, approximately half of the AF patients 
and non-AF controls had D-dimer levels exceeding the cut-off value in the LA sample, 
while median values of D-dimer were well below the cut-off in the FV samples (0.26 
mgFEU/L (IQR: 0.17–0.48 mgFEU/L) and 0.30 mgFEU/L (IQR: 0.18–0.48 mgFEU/L) 
in AF patients and controls, respectively). 
  
 32 
Elevated Factor VIII and von Willebrand Factor Levels 
Predict Unfavorable Outcome in Stroke Patients Treated with 
Intravenous Thrombolysis 
Study Population 
During the study period, 131 consecutive AIS patients receiving intravenous rt-PA 
treatment were enrolled. In case of six patients, intravenous thrombolytic therapy was 
supplemented with intra-arterial thrombolysis using rt-PA according to standard 
protocol; the duration of thrombolysis and the final dose of rt-PA applied did not 
significantly differ for these patients. Median age of the patient cohort was 69 (IQR: 
59–79) years, 60.3% were men. The most common cerebrovascular risk factor was 
arterial hypertension in this patient cohort (n= 100, 76.3%). Median time from symptom 
onset to treatment was 155 min (IQR: 125–180). Median NIHSS before stroke treatment 
was 8 (IQR: 5–14). According to the TOAST criteria, etiology of stroke was most 
commonly large vessel disease (n= 49, 37.4%), followed by 27 (20.6%) patients with 
cardioembolic stroke. As detected by CTA on admission, 70 patients (53.4%) had a 
vessel occlusion, and 27 patients (20.6%) stenosis. Poor functional outcome at 7 days 
post-event was observed in 20 cases (15.3%), while poor outcome at 90 days (mRS ≥3) 
was observed in case of 51 (38.9%) patients. Therapy-associated intracranial 
hemorrhage was detected in 13 cases, of which 6 cases (4.6%) were symptomatic 
according to ECASS II. Mortality rates by day 7, 14, and day 90 post-event were 3.8, 
6.1, and 22.1%, respectively. 
The Effect of Thrombolysis on FVIII Activity and VWF Antigen Levels 
In the samples taken on admission, the median values of both hemostasis parameters 
were above the upper limit of the respective reference interval in the whole patient 
cohort (FVIII activity median: 188.0%, IQR: 153.0–242.0%, VWF antigen level 
median: 201.3%, IQR: 169.1–259.6%). FVIII activity dropped significantly in the 
samples obtained immediately after thrombolysis as compared to the initial values 
(median: 102.0%, IQR: 62.0–155.5%, p <0.001) and showed an increase 24 h after the 
event (median: 166%, IQR: 130.0–209.0%, p= 0.014). On the contrary, VWF levels 
increased steadily post-lysis (median VWF levels immediately after lysis: 229.1%, IQR: 
157.6–293.3%, at 24 h post-lysis: 231.6%, IQR: 176.8–284.8%, Friedman’s two-way 
ANOVA p= 0.002). Notably, VWF median and IQR values were above the upper limit 
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of the reference interval at all investigated time points in the study cohort.  
Factor VIII activity and VWF antigen levels showed good correlation on admission (r= 
0.748, p <0.001), but no significant correlation was found immediately after 
thrombolysis (r= 0.093, p= 0.299), most probably due to plasmin mediated FVIII 
degradation. Fair correlation was observed between the two parameters in the samples 
obtained 24 h after thrombolysis (r= 0.420, p <0.001). 
The Association of FVIII Activity and VWF Antigen Levels with Stroke 
Severity 
Von Willebrand factor antigen levels were gradually and significantly elevated in case 
of more severe AIS (NIHSS 6–16 and NIHSS >16) at all investigated time points, but 
no such significant association was observed for FVIII activity levels. The association 
between VWF antigen levels and stroke severity remained significant after adjustments 
for confounders (current smoking, hsCRP, age) in the statistical model.  
The association of elevated VWF levels and more severe AIS was also proved as 
significantly higher VWF levels were found at all investigated time points in patients 
presenting with worse 24 h post-lysis CT scans (ASPECTS score 7–0). Similar 
association was observed for FVIII levels, except for the samples investigated 
immediately after lysis. Associations for VWF levels and FVIII activity remained 
significant after adjustments for confounders (current smoking, hsCRP, age) in the 
statistical model. As CT scans on admission are not indicative of stroke severity and 
have less predictive values as the ASPECTS at 24 h post-lysis, it was not surprising that 
no significant association was found between the investigated hemostasis parameters 
and the ASPECTS on admission.  
No association was found between FVIII activity and VWF antigen levels at any time 
points and stroke subtypes according to TOAST criteria (data not shown).  
FVIII activity at 24 h post-lysis was significantly elevated in patients with vessel 
occlusion (median: 175.0%, IQR: 151.5–227.0%) as compared to those with stenosis 
only (median: 137.0%, IQR: 98.5–175.0%) or without occlusion/ stenosis (median: 
142.0%, IQR: 115.0–177.0%) (p= 0.001), while such association was not observed for 
VWF levels. 
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Elevated FVIII Activity and VWF Antigen Levels As Predictors of 
Thrombolysis Outcomes 
Short-term outcome. Factor VIII activity and VWF antigen levels were not associated at 
any investigated time points with short-term therapy outcomes as assessed by the 
changes in NIHSS score by day 7 post-lysis.  
Risk of Intracranial Hemorrhage. No association was found between FVIII activity or 
VWF antigen levels at any investigated time points and therapy-associated ICH, except 
for higher VWF at 24 h post-lysis in patients presenting with SICH (median: 226.8%, 
IQR: 176.5–279.4% vs. median: 347.5%, IQR: 263.3–372.1% for no bleeding or aSICH 
vs. SICH, p= 0.017).  
Long-term outcome. Poor functional outcome (mRS ≥3) at 90 days post-event was 
associated with traditional risk factors including advanced age, increased NIHSS on 
admission, elevated hsCRP, and the presence of diabetes/diabetes treatment. Moreover, 
as expected, ASPECTS at 24 h post-lysis and the level of vessel occlusion as detected 
by CTA was also indicative of the long-term outcome. Among the hemostasis 
parameters investigated at various time points, elevated FVIII activity 24 h post-lysis 
and elevated VWF antigen level measured immediately after lysis and 24 h after therapy 
showed significant association with poor outcomes.  
Both parameters, as measured immediately post-lysis and 24 h post-lysis conferred a 
significant PPV and NPV for poor functional outcomes (highest PPV: VWF 24 after 
thrombolysis: 0.83; 95% CI: 0.59–0.96, p= 0.009 and highest NPV: FVIII immediately 
after thrombolysis: 0.73; 95% CI: 0.50–0.89, p= 0.009).  
A binary backward logistic regression model including age, gender, elevated hsCRP, 
active smoking, diabetes mellitus, and NIHSS >5 on admission revealed that a FVIII 
activity and VWF antigen level above the upper limit of the reference interval (168 and 
160%, respectively) as measured immediately after lysis and 24 h after thrombolysis 
significantly and independently increase the risk of unfavorable functional outcomes at 
90 days. In this model, FVIII activity and VWF antigen levels on admission did not 
prove to have an independent prognostic value regarding poor functional outcomes at 
90 days, while elevated FVIII and VWF levels immediately after thrombolysis 
conferred an independent OR: 7.09 (IQR: 1.77–28.38, p= 0.006) and OR: 6.31 (IQR: 
1.83–21.7, p= 0.003), respectively. Elevated levels of both factors 24 h after lysis were 
also found to have a significant predictive value (OR: 4.67, IQR: 1.42–15.38, p= 0.011 
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for FVIII activity and OR: 19.02, IQR: 1.39–187.0, p= 0.012 for VWF antigen level). 
Besides these hemostasis parameters, only hsCRP >5.2 mg/L and NIHSS >5 on 
admission remained in the stepwise backwards regression analysis model as 
independent risk factors for poor outcomes at 90 days (OR: 4.85, 95% CI: 1.64–14.33, 
p= 0.004 and OR: 3.51, 95% CI: 1.17–10.57, p= 0.026, respectively). 
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Discussion 
 
Intracardiac Hemostasis and Fibrinolysis Parameters in 
Patients with Atrial Fibrillation 
Although it is a general belief that in AF the intracardiac milieu is more thrombogenic 
than the peripheral blood, supporting pieces of evidence derived from measurements 
using intracardiac blood samples are scarce. In this study, we investigated the levels of a 
comprehensive list of hemostasis and fibrinolysis markers from intracardiac blood 
samples of AF patients and non-AF controls and failed to detect significant AF-specific 
alterations of hemostasis or fibrinolysis in intracardiac blood samples. It is to be noted, 
however, that only two patients experienced paroxysmal AF periods during the 
procedure, which means that most patients were on sinus rhythm during blood 
sampling. Our results suggest that as compared to peripheral samples, paroxysmal and 
persistent AF patients have no significant alterations in the intracardiac levels of the 
investigated hemostasis and fibrinolytic parameters, at least when they are not 
experiencing AF periods.  
Although significant local differences were observed for certain coagulation activation 
and fibrinolytic markers (namely, for FM, TAT complex, PAP complex, and D-dimer 
levels) in the intracardiac samples as compared to the FV samples, the same differences 
were found in non-AF control individuals. Moreover, in the LAA sample of both 
groups, a general tendency of decrease was observed in the level of most investigated 
markers as compared to LA samples. In earlier studies in which non-AF control 
population was not investigated, these differences were attributed to AF 
pathophysiology. However, our results imply that changes in the level of these markers 
are not specific to AF and are likely to be attributed to the invasive nature of the 
catheterization procedure, including transseptal puncture and tissue damage.  
Among all investigated hemostasis and fibrinolysis parameters, only the elevation of 
FVIII and VWF levels was found to be AF-associated in our study. Interestingly, FVIII 
and VWF levels were significantly elevated in both peripheral and intracardiac blood 
samples of AF patients as compared to controls. Elevation of VWF levels was 
particularly considerable in the AF patient group as the medians of VWF levels were at 
the upper limit of the reference interval in all sample types. Although the levels of VWF 
in AF patients have been studied earlier using peripheral samples, the relationship 
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between intracardiac and peripheral VWF levels has been obscure. An elevation of 
FVIII and VWF has been described earlier in the peripheral samples of AF patients and 
it has been proposed to be attributed to endothelial damage. Moreover, elevated levels 
of VWF have been associated with increased stroke risk and poor prognosis. Only few 
papers enrolling a limited number of patients have investigated the levels of VWF in AF 
patients from both intracardiac and peripheral blood samples, but in these studies FVIII 
levels were not determined. In line with our findings, in these earlier reports it was 
found that VWF levels were similar in the intracardiac samples and in samples obtained 
from the peripheral sampling site. In our study FVIII and VWF levels showed good 
correlation in all sample types, suggesting that they were in complexed form. As both 
proteins are stored in the Weiber-Palade bodies of the endothelium, these results imply 
that the elevation of VWF and FVIII levels are the consequence of endothelial damage 
and not necessarily restricted to the LA. It has to be noted that in the LAA of patients a 
similar tendency of FVIII and VWF elevation was observed as in case of FV and LA 
samples, but this is most likely due to the limited number of LAA samples since 
differences were not proved to be significant between patients and controls for this 
sample type.  
Despite the important role of the fibrinolytic system in preventing intravascular 
thrombosis, previous studies have paid little attention to the investigation of fibrinolytic 
abnormalities associated with AF. Moreover, little is known about the levels of 
important regulators of fibrinolysis in intracardiac samples in AF. Here we assessed a 
series of fibrinolytic markers from both peripheral and intracardiac blood samples of AF 
patients and non-AF controls. Besides a small but significant decrease in the levels of 
plasminogen in the LAA samples of AF patients as compared to the FV samples, no 
significant differences were observed between AF patients and non-AF controls and 
among sample types concerning FXIII activity, 𝛼�2-plasmin inhibitor, PAI-1 activity, 
and plasminogen activity measurements. There were no differences between PAP 
complex and D-dimer levels in AF patients and non-AF controls either. These findings 
suggest that the investigated components of the fibrinolytic system are mostly unaltered 
in AF. 
Limitations 
Our study has some limitations. First, the number of patients enrolled in the study was 
limited, which was obviously due to the highly invasive nature of blood sampling, 
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during which technical difficulties were often encountered. We would like to highlight, 
however, that the number of patients enrolled in our study is still more than the average 
number of patients undergoing this kind of blood sampling as published so far. 
Moreover, in our study a non-AF control patient group was also enrolled, which was 
often missing from earlier studies. Despite the particularly difficult and potentially risky 
technique of LAA sampling, a considerable number of patients were sampled from the 
LAA as well, which is a rarity in the literature as of yet. Based on our findings larger 
studies are warranted to corroborate our observations.  
Second, most patients enrolled in the study had low or moderate stroke risk according to 
the CHADS2 or CHA2DS2-VASC score, which limits the extrapolation of our findings 
to the general AF patient population. It has to be noted, however, that the stroke risk of 
our patient population reflects the current practice of most ablation centers, which offer 
ablation for younger patients with mostly paroxysmal AF, structurally normal heart, and 
no significant comorbidity. In addition, the necessity and safety of the discontinuation of 
anticoagulation preablation (which was a requirement in our study in order to carry out 
certain measurements) are only evident in low-risk patients.  
Third, only 2 patients experienced a paroxysmal AF period during the catheterization 
and blood drawing procedure. Naturally, more patients having AF period during 
sampling could have supplemented our results with a further interesting aspect. 
Conclusion 
AF patients have elevated FVIII and VWF levels, most likely due to endothelial 
damage, which is present in the intracardiac and peripheral environment as well. 
Intracardiac activation of hemostasis and fibrinolysis was demonstrated in AF patients 
and in non-AF controls to a similar extent, indicating that this might be a consequence 
of the catheterization procedure itself rather than a footprint of AF pathophysiology.  
 
 
Elevated Factor VIII and von Willebrand Factor Levels 
Predict Unfavorable Outcome in Stroke Patients Treated with 
Intravenous Thrombolysis 
In this study, we examined the levels of FVIII and VWF during thrombolysis in 131 
consecutive AIS patients and studied the relationship between the hemostasis factor 
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levels and stroke characteristics and therapy outcomes. Only few papers are found in the 
literature studying the changes of certain hemostasis factors during the course of 
thrombolysis following ischemic stroke and to our knowledge, none of them studied the 
levels of FVIII and VWF comprehensively in this respect. It has been known for almost 
40 years that in vitro plasmin degrades and inactivates FVIII. Studies in animal models 
also suggested such effect of plasmin on FVIII; however, the in vivo effect of plasmin 
on FVIII in humans during the course of rt-PA induced thrombolysis has not yet been 
characterized. Here we showed that FVIII activity drops significantly immediately after 
thrombolysis as compared to levels measured on admission of patients. However, as the 
vast majority of patients had elevated FVIII levels on admission, this reduction is most 
probably due to plasmin-mediated degradation, and did not reach a level that would 
suggest a potential risk for intracerebral hemorrhage. In fact, FVIII levels measured at 
any point in time in this study were not associated with bleeding complications, which 
is in line with the results of studies in animal models. As opposed to FVIII activity, 
VWF antigen levels showed a rising tendency during the course of thrombolysis in our 
study. This, in theory might be due to two reasons. The first apparent reason is VWF 
degradation by plasmin, which has been shown before in vitro. As the test we used for 
measuring VWF antigen levels contains polyclonal antibody against VWF, the 
degradation of the protein leads to an increased antigen level. In an early paper 
describing the time course of certain hemostasis factors in a few patients (n= 7) with 
AMI treated by rt-PA induced thrombolysis, it was shown that thrombolysis treatment 
resulted in the elevation of VWF antigen levels, most probably due to the proteolysis of 
VWF multimers. The degradation of VWF multimers has been speculated to be a 
potential causative factor for hemorrhagic complications in AMI patients treated with 
thrombolysis. In our study, VWF antigen levels were found to be significantly higher at 
24 h post-lysis in patients with SICH as compared to the rest of the cohort, but due to 
the relatively low number of patients with SICH in this population (n= 6), this 
association should be confirmed by other studies. As for the second reason for the 
elevation of VWF antigen levels post-lysis, it is plausible that the increase is due to 
endothelial damage caused by ischemic damage. Studies in AMI patients suggested that 
thrombolysis induced by streptokinase is associated with an increase of VWF antigen 
levels due to endothelial damage as a result of oxidative stress caused by the 
thrombolytic agent. Interestingly, in our study, VWF antigen levels showed an increase 
after thrombolysis only in patients with more severe stroke (NIHSS 6–16 and 
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NIHSS >16 on admission), while in the group of patients with less severe stroke 
(NIHSS 0–5) this elevation was not seen, suggesting that at least in part endothelial 
dysfunction is likely to contribute to this finding.  
Many studies have investigated the association between FVIII and/or VWF levels and 
the risk of cardiovascular or cerebrovascular events. Despite few conflicting results, it 
has been well established that elevated FVIII and/or VWF levels predispose patients to 
AIS. In line with our findings, most studies revealed that in the majority of tested 
patients with AIS, high FVIII and VWF levels were found; moreover, baseline stroke 
severity as measured by the NIHSS score was associated with elevated FVIII and/or 
VWF levels. Furthermore, beyond these previously known results, here we describe a 
strong association between elevated FVIII/VWF levels during the course of 
thrombolysis and the ASPECT score in patients as assessed 24 h post-lysis. The only 
non-significant association in this respect was FVIII activity tested immediately after 
lysis, which was most probably due to plasmin-mediated degradation of the protein. The 
finding that the ASPECT score the day after stroke shows a strong association with the 
tested hemostasis parameters is of considerable interest, as it indicates a link between 
the investigated factors and stroke severity as verified by not only the NIHSS functional 
score but by imaging analysis as well. Similar findings on the relation of any hemostasis 
factors and the results of such imaging analysis is practically lacking in the literature as 
of yet.  
Limited evidence is available on the possible association of FVIII/VWF levels with the 
etiology of stroke; moreover, reports are often discordant in this respect. Here, we could 
not find any association of FVIII/VWF levels with the subtype of stroke as classified by 
the TOAST criteria.  
While the association between VWF levels and thrombolysis outcome following AMI 
has been studied before, surprisingly, similar data regarding ischemic stroke are much 
more limited. Here we show that a FVIII activity and VWF antigen level above the 
upper limit of the reference interval, as measured immediately after or 24 h post-lysis, 
confer a significant, independent risk for poor functional outcomes at 90 days post-
event.  
Our results indicate that both factors could be useful biomarkers having significant 
prognostic values on long-term outcomes, which might help with patient selection 
requiring alternative treatment post-lysis. At the same time, at least according to results 
of this cohort, pre-treatment FVIII and VWF levels were not indicative of thrombolysis 
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outcomes.  
Although here we propose that our results have prognostic value in the studied patient 
cohort, nevertheless, we consider the relevance of our findings as potentially useful 
descriptive data which might provide basis for future research, while its clinical 
relevance remains to be fully elucidated. In the era of mechanical thrombectomy, the 
management of AIS faces new types of decision-making questions in the clinical 
practice. Useful biomarkers with predictive values regarding poor outcomes might be 
incorporated into algorythms designed to select candidates for alternative approaches 
rather than rt-PA alone, e.g. mechanical thrombectomy or other pharmacological 
approaches. Moreover, studies on VWF in particular might prove even more useful in 
the future, as preclinical and clinical studies on inhibitors of VWF are promising and 
show a safe antithrombotic potential. When used in combination with t-PA, VWF 
antagonists were able to prevent ongoing microvascular thrombus formation reducing 
stroke progression. These findings are particularly interesting in the light of our 
observations showing that VWF median and IQR values were constantly above the 
upper limit of the reference interval in the studied AIS population. Although drugs that 
target the inhibition of the action of VWF have not yet reached approval for the market, 
studies on FVIII/VWF levels during stroke and thrombolysis might provide useful 
descriptive data to understand the pathophysiology relevant to the potential clinical 
application of these inhibitors in humans in the future. 
Limitations 
Our study has limitations. The sample size is limited, but in the light of other studies on 
AIS patients treated by thrombolysis it is considered representative. Due to the limited 
number of patients with SICH and with poor outcomes in this cohort, despite the 
significant associations found, results presented here need to be verified by larger 
studies. We did not investigate AIS patients who were not suitable for rt-PA therapy. In 
theory, measuring FVIII/VWF levels of patients receiving and not receiving rt-PA and 
comparing the results with outcomes might be useful. However, due to the important 
baseline differences between the two groups (e.g. the group not receiving rt-PA might be 
highly heterogeneous regarding time window from symptom onset, baseline coagulation 
screening tests, effective anticoagulation, age, etc.) which may significantly affect the 
results, such comparison might fail to support relevant conclusions.  
The lack of advanced neuro-imaging (e.g. perfusion and collateral circulation imaging) 
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limits the application of this study.  
Finally, as the study was designed to find potential biomarkers with predictive values 
for long-term outcomes following thrombolysis, we did not perform any functional 
characterization studies on the plasmin-mediated effect of FVIII and VWF proteins. In 
case of FVIII activity, we assumed based on previous studies, that the reduction in 
activity levels as detected immediately after thrombolysis is due to plasmin-mediated 
degradation and did not perform any biochemical tests to prove this hypothesis. In case 
of VWF, functional activity tests, including ristocetin induced activity tests, collagen-
binding assay, multimer testing, etc. were not measured in the patient population. Future 
studies are required to elucidate whether the qualitative changes of both proteins 
following stroke and thrombolysis would have any pathophysiological relevance and 
prognostic value.  
Conclusion 
Here we report the changes in FVIII activity levels and VWF antigen levels during the 
course of thrombolysis in a cohort of consecutive AIS patients. Elevated FVIII activity 
and VWF antigen levels immediately after lysis and 24 h post-therapy were shown to 
have independent prognostic values regarding poor functional outcomes at 90 days. 
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Summary of discussion 
Cardiovascular and cerebrovascular diseases are among the leading causes of death in 
developed countries. Although these groups of diseases have been intensively 
researched because of their public health significance, better understanding of their 
pathomechanism and identifying biomarkers, predicting the risk of developing cardio- 
and cerebrovascular diseases and/or having prognostic value, remain a challenge. 
One of the most serious complication of atrial fibrillation is cardiembolic ischemic 
stroke. Cardioembolic stroke occurs in approximately 21-37% cases of ischemic stroke. 
According to literature data, studying VWF in patients with atrial fibrillation may be a 
useful biomarker for cardioembolic ischemic stroke and may complement the currently 
used clinical scales using only anamnestic data. Our studies confirm the presence of 
increased VWF and associated elevated FVIII levels in patients with atrial fibrillation 
compared to non-atrial fibrillation controls. Our results also highlighted that the rate of 
increase is similar in intracardial and peripheral blood. Based on our results, FVIII and 
VWF may be useful biomarkers after the thrombolysis therapy of ischemic stroke, 
predicting post-thrombolysis severity and long-term outcome. Examination of the two 
parameters can help to better understand the causes of therapeutic failure, and the 
knowledge gained can provide a starting point in the future to develop alternative 
therapeutic approaches. At the same time, it should be emphasized that further 
investigation of the changes in the hemostasis parameters we have studied in both atrial 
fibrillation and ischemic stroke, and the results discussed in the thesis need to be studied 
with a larger population. 
 
Summarizing our results, elevated FVIII and VWF levels may indicate thromboembolic 
risk associated with atrial fibrillation, while elevated FVIII and VWF levels after 
thrombolytic therapy in ischemic stroke are independent predictors of adverse long-term 
outcomes.   
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The candidate's own results and new findings 
 
 By examining several markers of the hemostasis and fibrinolytic system in the 
intracardiac and peripheral blood samples of AF patients and non-AF controls, 
FVIII activity and VWF antigen levels were found to be significantly increased 
in AF patients in intracardiac and peripheral blood samples as well. Good 
correlation between FVIII activity and VWF levels suggests that elevated levels 
may be due to endothelial damage. 
 Blood samples obtained from the left atrial appendage were not associated with 
increased prothrombotic differences in AF patients and non-AF controls as 
compared to blood samples obtained from the left atrium.  
 Among the examined hemostasis or fibrinolysis parameters, local (intracardial), 
atrial fibrillation-specific differences were not detected. However, local 
(intracardial) non-atrial fibrillation-specific differences were observed in case of 
several parameters. We found that TAT complex, FM, PAP complex, D-dimer 
levels were significantly higher in the left atrium blood samples in both AF and 
non-AF groups. The elevated levels of these parameters during catheterisation 
indicated non-atrial fibrillation-specific transient thrombotic risk in both patient 
cohorts. 
 By investigating blood samples of patients undergoing intravenous thrombolytic 
therapy following acute ischemic stroke prior to thrombolysis, immediately after 
thrombolysis and 24 hours after thrombolysis, we established that the VWF 
antigen level medians and the lower limit of the interquartile range were above 
the reference range in the tested patient cohort. The median FVIII activity prior 
to thrombolysis also exceeded the upper limit of the reference range but showed 
a significant reduction immediately after thrombolysis and increased again 24 h 
after thrombolysis. 
 We observed that VWF antigen levels were significantly higher in patients with 
more severe stroke (NIHSS> 16 and NIHSS 6-16) as compared to patients with 
mild stroke (NIHSS <6) in blood samples taken prior to thrombolysis. In 
patients with more severe stroke, VWF antigen levels gradually and significantly 
increased after thrombolysis. Elevated VWF antigen levels as observed 24 hours 
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after thrombolysis showed significant correlation with the occurrence of 
symptomatic intracranial bleeding in the studied population. 
 The relationship between more severe acute ischemic stroke and elevated VWF 
antigen levels was also supported by the observation that worse ASPECT score 
in the control radiological examination 24 h post-event was associated with 
significantly higher VWF antigen levels at all sampling occasions. FVIII as 
measured immediately after thrombolysis did not have significant correlation 
with an unfavorable ASPECT score determinated at 24 h post-event, but there 
was a significant correlation between unfavorable ASPECT scores at 24 h post-
event and elevated FVIII activity levels as measured in samples prior to 
thrombolysis and 24 h after thrombolysis. 
 We observed good correlation between FVIII activity and VWF antigen levels 
(r=0.748, p <0.001) in blood samples prior to thrombolysis. However, there was 
no significant correlation immediately after thrombolysis, which is surmized to 
be due to plasmin-mediated FVIII degradation. 
 Using a multivariate logistic regression model, we demonstrated that elevated 
FVIII and VWF antigen levels detected immediately after and 24 hours after 
thrombolysis were independent risk factors of unfavorable long-term functional 
outcomes (mRS 90 days later thrombolysis ≥3) (immediately after thrombolysis 
FVIII: OR: 7.1, 95% CI: 1.8-21.7, p= 0.003, 24 hours after lysis: FVIII OR: 4.7, 
95% CI: 1.4-15.4, p= 0.011, VWF: OR: 19.0, 95% CI: 1.9-187.0, p= 0.012). 
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Summary 
Introduction. Cardiovascular and cerebrovascular diseases, as the leading causes of 
mortality and long-term morbidity are intensively investigated disorders. Still, today the 
understanding of their pathomechanism as well as the identification of biomarkers as 
potential risk factors and/or prognostic markers remain a challenge.  
Patients and methods. We have carried out two observational clinical studies in order to 
investigate the levels of certain hemostasis and fibrinolytic factors, particularly factor 
VIII (FVIII) and von Willebrand factor (VWF) in patients with atrial fibrillation and 
acute ischemic stroke. The first patient group consisted of 24 patients with atrial 
fibrillation and 14 patients with other supraventricular tachycardia (controls) 
undergoing transcatheter radiofrequency ablation. Blood samples were drawn from the 
femoral vein, left atrium and left atrial appendage before the ablation procedure. FVIII 
activity, VWF antigen level, fibrinogen, factor XIII, α2 plasmin inhibitor activity, 
thrombin-antithrombin (TAT) complex, quantitative fibrin monomer (FM), 
plasminogen, plasmin-α2 antiplasmin (PAP) complex, PAI-1 activity, and D-dimer were 
measured from all samples. The other study population included 131 consecutive acute 
ischemic stroke patients who underwent i.v. thrombolysis with recombinant tissue 
plasminogen activator (rt-PA). Blood samples were taken on admission, 1 and 24 h after 
rt-PA administration to measure FVIII activity and VWF antigen levels. Results were 
compared to stroke severity and to short- and long-term clinical outcomes.  
Results. In atrial fibrillation patients, FVIII activity and VWF antigen levels were 
significantly elevated in intracardiac and peripheral blood samples as compared to 
controls. TAT complex, FM, PAP complex and D-dimer levels were significantly 
elevated in the intracardiac samples of both groups, indicating a temporary thrombotic 
risk associated with the catheterization procedure. When investigating ischemic stroke 
patients, significantly elevated VWF levels were detected on admission in case of more 
severe stroke. In a binary backward logistic regression analysis elevated FVIII and 
VWF levels after thrombolysis were independently associated with poor long-term 
functional outcomes (immediately after thrombolysis FVIII: OR:7.1, 95% CI: 1.7-28.4, 
p=0.006; VWF: OR: 6.31, 95% CI: 1.8-21.7, p=0.003). 
Conclusions. Elevated FVIII and VWF levels might predict increased thromboembolic 
risk in atrial fibrillation patients, while in case of ischemic stroke patients, elevated 
FVIII and VWF levels after thrombolysis are independent predictors of poor long-term 
functional outcomes.  
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